Nanoliposomal oxaliplatin ameliorates chemotherapy-induced neuropathy.
Alaei M, Moetamani-Ahmadi M, Mahaki H, Fiuji H, Maftooh M, Hassanian SM, Khazaei M, Shahri AP, Ferns GA, Frozanfar F, Tanzadehpanah H, Avan A.
Alaei M, et al.
Neurosci Lett. 2023 Aug 24;812:137367. doi: 10.1016/j.neulet.2023.137367. Epub 2023 Jul 5.
Neurosci Lett. 2023.
PMID: 37419304
Chemotherapy-induced peripheral neuropathy (CIPN) is an important adverse effect of treatment with oxaliplatin (OXA). We have developed PEGylated nanoliposomal oxaliplatin (OXA-LIP) and tested its activity in an animal model of CIPN. ...OXA had a significantl …
Chemotherapy-induced peripheral neuropathy (CIPN) is an important adverse effect of treatment with oxaliplatin (OXA). We have develop …